See Beyond the Expected.
Our team’s mission and vision for earlier detection of Leptomeningeal Metastases
At CNSide® Diagnostics, LLC, our company’s Mission is to revolutionize the clinical management of patients with Leptomeningeal Metastases (LM) through innovative diagnostic solutions.
Our company’s Vision is to improve patient outcomes by delivering cutting-edge diagnostics that enable personalized and effective treatment strategies.
Leadership Team
Russell Bradley
President & General Manager
Marc Hedrick, MD, MBA
President & CEO, Plus Therapeutics
Russ Havranek, MS, MBA
EVP, Commercial & Corporate Strategy
Jonathan Stein, PhD, HCLD(ABB)
Chief Medical Director
Andrew Brenner, MD, PhD
Professor of Medicine & Neuro-Oncology
Andrew Sims, CPA
CFO & VP of Finance
Consolidated Clinical Laboratory & Manufacturing Facility in Houston, Texas
Full vertical integration in single facility
- Centrally located in the U.S. for efficient shipping and logistics
- Includes on-site advanced imaging, molecular analysis, cell-handling
- In-house manufacturing of key test components with ability to scale:
- CEE-Sure® CSF collection tube preservative
- Antibody mix
- Microfluidic chip
- Licensed with the Clinical Laboratory Improvement Amendments (CLIA) from the Centers for Medicare and Medicaid Services (CMS): CLIA Certificate of Accreditation 45D2308861
- Lab Director: Jonathan Stein, PhD, HCLD (ABB)
Our History
The CNSide® Cerebrospinal Fluid (CSF) Assay Platform was originally developed as a more sensitive and informative method for detecting and analyzing cancer cells in CSF compared to traditional CSF cytology. CNSide® was initially launched in the U.S. by another company as a commercial assay in 2021. In 2022 and 2023, Plus Therapeutics partnered with and licensed the CNSide® technology from that company to support its own ReSPECT-LM clinical trials and potential commercialization of the REYOBIQ targeted radiotherapeutics for Leptomeningeal Metastases (LM). Plus Therapeutics acquired all CNSide® assets and established a new subsidiary, CNSide® Diagnostics, LLC, in 2024. The company is now focused on commercializing the CNSide® CSF Assay Platform, starting with the Tumor Cell Enumeration (TCE) test in the state of Texas in 2025.
Careers
There are no available positions at this time.
For consideration of future opportunities, you can email your resume to HR@cnside-dx.com.